BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Prima Biomed (PRR.AX) to Host Shareholder Briefing


5/31/2012 8:49:57 AM

SYDNEY, AUSTRALIA--(Marketwire - May 31, 2012) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (Prima, the Company) advises that it will hold a shareholder briefing with the Company's CEO designate Matthew Lehman, current CEO Martin Rogers, Chairman Lucy Turnbull, and Deputy Chairman Albert Wong in Sydney, Australia, on Friday, 15 June 2012.

The briefing will provide an opportunity for Mr. Lehman to meet shareholders and deliver an update on the Company's activities.

Mr. Lehman, who is currently Prima's Chief Operating Officer, will become the Company's CEO effective 1 September 2012 (see ASX announcement of 24 May).

Details of the shareholder briefing:

Date:
Friday, 15 June 2012

Time:
9:30am to 11:00am AEST (local time)

Venue:
Radisson Blu Hotel Sydney
27 O'Connell St Sydney (Marble Room 2 and 3)

Shareholders outside Sydney will be able to access the briefing via a webcast and dial-in facility. Webcast and dial-in details will be provided on the Prima BioMed and ASX websites prior to the meeting.

Shareholders, and other interested parties, are kindly requested to RSVP to enquiries@primabiomed.com.au prior to the event to assist in planning the meeting. Shareholders are also encouraged to submit questions or comments via email prior to the meeting.

Prima has updated the Company Calendar section of its website to include this shareholder briefing and other relevant upcoming public presentations.

About Prima BioMed

Prima BioMed is a global biotechnology company headquartered in Australia. As a leader in personalised bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximise value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer.


For further information please contact:

Australia Investor/Media:
Mr. James Moses
Mandate Corporate
+61 (0) 420 991 574
Email Contact

USA Investor/Media:
Ms. Kathy Galante
Burns McClellan Inc.
+1 (212) 213-0006
Email Contact

Europe Investor/Media:
Mr. Axel Mühlhaus
edicto GmbH
+49 (0) 69 905505-52
Email Contact


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->